在败血症休克中对第三线 ангиотензин-II 与上腺素的临床反应:一种倾向匹配的队列研究
Caitlyn R Blankenship1, Kevin D Betthauser1, Laura N Hencken1
1Department of Pharmacy Practice, Barnes-Jewish Hospital, St. Louis, MO, USA.
The Annals of pharmacotherapy
|February 2, 2024
概括
第三线 ангиотензин-II (AT-II) 在败血症休克中与上腺素相比没有显著改善临床反应. 需要进一步的研究来探索AT-II.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 重症监护室的重症监护室的重症监护室.
背景情况:
- 败血性休克管理需要有效的血管压缩剂.
- 在北上腺素和血管压素之后,最佳的第三线血管压缩剂尚未确定.
- ангиотензин-II (AT-II) 为耐火性败血性休克提供了一个新的机制.
研究的目的:
- 为了比较第三线 ангиотензин-II (AT-II) 与上腺素在败血性休克患者的疗效和安全性.
- 评估接受第三线血管压缩剂的患者的临床反应和安全结果.
主要方法:
- 追溯队列研究 (2019年4月至2022年7月).
- 接受第三线AT-II与上腺素的败血症休克患者的倾向匹配分析 (2:1).
- 主要结局:启动后24小时的临床反应.
主要成果:
- 47.8%的AT-II患者获得了临床反应,而28.3%的上腺素患者 (P=0.12).
- 两组之间在住院死亡率,心律失常或血栓塞栓症方面没有显著差异.
- 研究不足以检测出统计学上显著的差异.
结论:
- 与上腺素相比,第三线AT-II与24小时内显著改善的临床反应无关.
- 临床观察表明,需要对AT-II进行进一步的研究.
- 上腺素仍然是一个可行的第三线选择,但AT-II需要更多的研究.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
778
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
778
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
734
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
734


